|
Encorafenib plus cetuximab with or without binimetinib for BRAF V600E metastatic colorectal cancer: Updated survival results from a randomized, three-arm, phase III study versus choice of either irinotecan or FOLFIRI plus cetuximab (BEACON CRC). |
|
|
Stock and Other Ownership Interests - MolecularMatch; Navire |
Consulting or Advisory Role - Amal Therapeutics; Amgen; AstraZeneca/MedImmune; Bayer Health; Biocartis; Boehringer Ingelheim; Boston Biomedical; Daiichi Sankyo; EMD Serono; EMD Serono; Genentech; Holy Stone Healthcare; Ipsen; Karyopharm Therapeutics; Lilly; Merck; Natera; Navire; Novartis; Pierre Fabre; Redx Pharma; Roche; Symphogen |
Research Funding - Amgen (Inst); Array BioPharma (Inst); Biocartis (Inst); EMD Serono (Inst); Genentech/Roche (Inst); Guardant Health (Inst); Lilly (Inst); MedImmune (Inst); Novartis (Inst); Sanofi (Inst) |
|
|
Honoraria - Aptitude Health; Elsevier; IMEDEX |
Consulting or Advisory Role - Amgen (Inst); Array BioPharma (Inst); Bayer (Inst); Boston Biomedical (Inst); Bristol-Myers Squibb (Inst); Daiichi Sankyo (Inst); Genentech/Roche; Lilly (Inst) |
Research Funding - Array BioPharma (Inst); Bayer (Inst); Boston Biomedical (Inst); Daiichi Sankyo (Inst); Eisai (Inst); Genentech/Roche (Inst); Lilly (Inst); Pfizer (Inst) |
Travel, Accommodations, Expenses - Amgen; Array BioPharma; Bayer; Boston Biomedical; Bristol-Myers Squibb; Genentech/Roche |
|
|
Consulting or Advisory Role - Array BioPharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Celgene; Halozyme; Lilly; Merck KGaA; Merck Sharp & Dohme; Novartis; Roche; SERVIER |
Research Funding - amgen (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Ipsen (Inst); Lilly (Inst); Merck (Inst); Merck KGaA (Inst); Novartis (Inst); Roche (Inst); SERVIER (Inst) |
|
|
Consulting or Advisory Role - Array BioPharma |
Research Funding - Array BioPharma; Boehringer Ingelheim; Novartis |
Travel, Accommodations, Expenses - Array BioPharma |
|
|
Honoraria - Array BioPharma; Celgene; ERYTECH Pharma; Merck KGaA; Roche/Genentech; Servier; Shire; Sirtex Medical |
Consulting or Advisory Role - ERYTECH Pharma; Incyte; Pierre Fabre; Roche Pharma AG; Shire; Sirtex medical |
Speakers' Bureau - Celgene; Merck KGaA; SERVIER; Sirtex Medical |
Research Funding - Merck KGaA (Inst); Merck Sharp & Dohme (Inst); Pfizer (Inst); Sirtex Medical (Inst) |
|
|
Research Funding - Chugai Pharma (Inst); Daiichi Sankyo (Inst); GlaxoSmithKline (Inst); MSD (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); PAREXEL International Inc. (Inst); Sanofi (Inst); Sumitomo Dainippon (Inst) |
|
|
Consulting or Advisory Role - Amgen (Inst); BeiGene; Biocon; Eisai; Lilly |
Research Funding - AstraZeneca/MedImmune (Inst); BeiGene (Inst); Bionomics (Inst); Bristol-Myers Squibb (Inst); GlaxoSmithKline (Inst); Lilly (Inst); Novartis (Inst); Roche (Inst) |
|
|
Consulting or Advisory Role - Amgen; Bayer; Merck KGaA; Pfizer; Roche/Genentech |
Research Funding - Amgen (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Ipsen (Inst); Merck KGaA (Inst); Merck Sharp & Dohme (Inst); Roche/Genentech (Inst); SERVIER (Inst); Symphogen (Inst) |
|
|
Consulting or Advisory Role - Amgen; Bayer; Sanofi |
Speakers' Bureau - Amgen; Bayer; Roche; Sanofi |
Research Funding - Amgen (Inst); Bayer (Inst); Merck Serono (Inst); Roche (Inst) |
Travel, Accommodations, Expenses - Amgen; Merck Serono; Roche |
|
|
No Relationships to Disclose |
|
|
Research Funding - AB Science (Inst); Abbvie (Inst); Actuate Therapeutics (Inst); Amgen (Inst); AstraZeneca/MedImmune (Inst); Bayer (Inst); Blueprint Medicines (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Cytovation (Inst); Deciphera (Inst); Genentech (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Incyte (Inst); InteRNA (Inst); Lilly (Inst); Merck Sharp & Dohme (Inst); Merus (Inst); Novartis (Inst); Pfizer (Inst); Pierre Fabre (Inst); Roche (Inst); Sanofi (Inst) |
|
|
No Relationships to Disclose |
|
|
Employment - Hospital Corporation of America |
Honoraria - BeiGene; Bicycle Therapeutics; Guardant Health; Merck KGaA; Roche; SERVIER |
|
|
Consulting or Advisory Role - Amgen; Merck Serono; Roche; Sanofi; SERVIER |
Speakers' Bureau - Amgen; Merck Serono; Roche; Sanofi; SERVIER |
Travel, Accommodations, Expenses - Merck Serono; Roche |
|
|
Employment - Alnylam (I); Array BioPharma; Bluebird Bio (I); Pfizer |
Stock and Other Ownership Interests - Alnylam (I); Array BioPharma; Bluebird Bio (I); Pfizer |
Patents, Royalties, Other Intellectual Property - Receives royalties from Yale University on an antibody used in nephrology basic research. (I) |
|
|
|
|
|
Employment - Array Biopharma; Pfizer |
Stock and Other Ownership Interests - Array BioPharma; Gilead Sciences |
|
|
Consulting or Advisory Role - Array BioPharma; AstraZeneca; Bayer; BeiGene; Biocartis; Boehringer Ingelheim; Chugai Pharma; Foundation Medicine; Genentech; Genmab; HalioDx; Halozyme; Imugene; Inflection Biosciences; Ipsen; Kura Oncology; Lilly; Menarini; Merck Serono; Merrimack; Merus; Molecular Partners; MSD; Novartis; Peptomyc; Pfizer; Pharmacyclics; ProteoDesign; Rafael Pharmaceuticals; Roche; Roche; Sanofi; Seagen; Seagen; Servier; Symphogen; Taiho Pharmaceutical; VCN Biosciences |